Summary In clinical trials with interferon a2b (IFN-a2b) as maintenance therapy for multiple myeloma, the therapeutic benefit is inconclusive. Although the mechanism(s) by which IFN-a2b prolongs remission in some patients is unknown, 2',5'-oligoadenylate synthetase (2,5-A synthetase) has been used as an objective indicator that IFN-a2b is active in vivo. The enzyme was assayed in cytosol preparations of peripheral blood mononuclear cells (MNCs) from 111 patients who were receiving IFN-a2b and 54 patients who were not, using an assay which measures the conversion of [a-32P]ATP to triphospho(adenylyl 2',5')adenosine. 2,5-A synthetase activity was compared with response to intensive therapy and with duration of maintenance therapy. Seventy-three per cent of patients had measurable amounts of 2,5-A synthetase during the first 6 months of maintenance therapy. This percentage decreased with longer follow-up but not significantly. There was no difference between the magnitude of enzyme induction amongst patients who were in complete remission, partial response or who had no change in disease status following intensive therapy. Peripheral blood T cells were a major source of 2,5-A synthetase activity in patients receiving the cytokine. However, both T and B cells produced the enzyme following exposure to IFN-a in vitro. The data show that the level of 2,5-A synthetase in patients with multiple myeloma is not indicative of clinical response to 
The interferons are a heterogeneous group of proteins that have pleiotropic effects as well as their known anti-viral activity. Interferon a (IFN-m) is the most widely used and is available commercially, from recombinant technology, as IFN-a2a (Roferon), IFN-a2b (Intron-A) and .
The therapeutic benefit of IFN-a as maintenance therapy for patients with multiple myeloma remains inconclusive. In the first randomised trial, the initial suggestion by Mandelli et al . (1990) that IFN-a might produce a survival benefit, following chemotherapy to objective response, was not confirmed with longer follow-up of the same patients (Avvisati et al., 1993) . Two other randomised trials produced similar results, although all three studies confirmed a significant prolongation of remission compared with patients who received no further treatment (Ludwig et al., 1991; Westin, 1993) . In three other randomised studies, maintenance therapy with IFN-a produced neither prolongation of remission nor a survival benefit (Peest et al., 1990; Bird et al., 1993; Salmon et al., 1994) . Results from a nonrandomised French study suggest that IFN-a can prolong remission after chemotherapy with autologous bone marrow rescue (ABMR) (Attal et al., 1992) . Also in an ongoing study at the Royal Marsden Hospital patients who were randomised to receive IFN-a2b after high-dose melphalan (HDM) and ABMR show a significantly longer duration of remission and survival compared with those who have had no further treatment (Cunningham et al., 1993) . However, in both of these studies the benefit of IFN-a was confined to patients who entered complete remission after ABMR. These data suggest that the efficacy of IFN-x in stabilising residual disease is greatest when there has been a substantial reduction of the tumour burden.
The mechanism(s) by which IFN-a stabilises remission in some patients is unknown. It has yet to be determined whether the cytokine acts directly by inhibiting the proliferation of the malignant clone or indirectly by immune modulation. Furthermore, it is not known whether IFN-a remains biologically active when given long term to patients, or whether it is necessary to give IFN-a throughout the duration of remission until relapse. We have shown previously that neutralising antibody production against IFN-a in patients who receive the cytokine as maintenance therapy is transitory and unlikely to account for relapse . However, recent evidence suggests that some cancer patients who receive IFN-a produce an inhibitor (IIF) which blocks the effects of the recombinant cytokine in vitro and is not antibody (Medenica et al., 1994) . This raises the possibility that IFN-a may be ineffective in some patients and may be wasteful of an expensive resource.
Treatment of cells with IFN-a results in the induction of 2'-5' oligoadenylate synthetase (2,5-A synthetase) which catalyses the polymerisation of ATP to triphospho(adenylyl 2',5')adenosine (Kerr and Brown, 1978; Baglioni, 1979) . This oligomer is required for the activity and stability of ribonuclease L which degrades mRNA and rRNA and consequently inhibits protein synthesis (Nilsen et al., 1981) . An increase in the activity of 2,5-A synthetase is a very sensitive indication that cells have been in contact with IFN-a. In patients, induction reaches a maximum approximately 8 h after the administration of the cytokine and elevated levels persist for at least 24h following cessation of treatment. However, the magnitude of enzyme induction in individual patients shows considerable variation (Merritt et al., 1985) . In patients with chronic lymphocytic leukaemia (CLL) receiving IFN-a, the degree of induction of mRNA for 2,5-A synthetase was statistically different between good, intermediate and poor responders, suggesting that measurement of the enzyme might be indicative of clinical response (de Mel et al., 1990) . Furthermore, although the exact role of 2,5-A synthetase in the action of IFN-a is unclear, in patients with hairy cell leukaemia and B-cell CLL its induction has been linked directly to the anti-proliferative effect of pentostatin (Ho et al., 1992 and counted in a P-counter in 10 ml of scintillation fluid (Ultima Gold; Packard, USA). Preliminary experiments were done to confirm the stability of the enzyme following freezing and thawing and the nature of the products which were mostly dimers (Minks et al., 1979; Merritt et al., 1985) . In addition, MNCs were assayed from a normal volunteer during two separate infectious episodes immediately and after incubation for 24 and 48 h to determine the half-life of 2,5-A synthetase, which was shown to be 24 h (data not shown).
Purification of B and T-cells
The number of T and B cells in MNC were estimated using dual-labelled fluorescence-activated cell analysis (FACS) with monoclonal antibodies conjugated to fluorescene isothiocyanate (FITC) or phycoerythrin (PE) and directed against CD19 and CD3 (Beckton Dickinson, UK,) and CD4, CD8, CD14 and CD45 (Sigma, UK) using an Ortho Cytoron and the software package provided by the manufacturer (Ortho Diagnostics Systems, UK). B and T cells were isolated using antibody coated magnetic beads conjugated to CD19 (B cell) or CD2 (T cell) with a bead to cell ratio of 3:1 and detached from the same by methods described by the manufacturer (Dynal, UK). Viable cells were counted in a haemocytometer using trypan blue exclusion. Isolated B and T cells were incubated at 2 x 106 ml-' in RPMI-1640 supplemented with 10% FCS, 100 gigml' penicillin and 100 Umlh' streptomycin and containing 100 U ml' IFN-a2b (Intron A) or the same volume of phosphate-buffered saline (PBS). After incubation for 20h, cells were harvested and processed as above. In experiments in which T cells were isolated from the peripheral blood of patients who were receiving IFN-a2b, cell extracts were prepared immediately after separation from the MNCs, without detachment from magnetic beads. The data in Table I show that 2,5-A synthetase activity was detected in 36/54 (67%) of patients with multiple myeloma who were not receiving maintenance therapy with IFN-a2b. These included nine patients who had had no previous chemotherapy. The remainder were patients who had had induction therapy alone (11 patients) or induction therapy followed by HDM/ABMR or PBSCR (16 patients). Since enzyme activity in these patients was likely to be due to infection which was documented in some patients after intensive therapy, the data suggest that their response to endogenous IFN was not impaired by intensive therapy. Three of 12 normal donors who were known to have infection at the time of testing also had measurable enzyme activity.
Amongst patients who were having maintenance therapy with IFN-a2b 73% had measurable 2,5-A synthetase activity during the first 6 months of treatment. With longer follow-up this percentage decreased but not significantly. There was considerable variation in the absolute amount of enzyme in individual patients, which showed no correlation with the clinical response to intensive therapy. Although there was a tendency for enzyme activity to decline with longer periods of maintenance therapy this was not statistically significant (Table I) . During the time period over which samples were accrued, peripheral blood from 8/22 patients who remain in CR after HDM/ABMR and who are included in the Royal Marsden Hospital Trial with IFN-a2b as maintenance therapy (Cunningham et al., 1993) was available for testing. Five of these eight patients had measurable levels of 2,5-A synthetase activity 34-72 months after commencing therapy with IFNa2b (Table II) .
Examination of sequential blood samples from individual patients shows that in three patients loss of 2,5-A synthetase activity was associated with relapse (Table III, patients 9, 12 and 14). Two of these patients had had PBSCR (patients nine and 14) and one had had ABMR (patient 12) after HDM. In one of these patients (patient 14) maintenance therapy with IFN-a2b was continued during progressive disease and the enzyme activity increased subsequently. Throughout the duration of maintenance therapy neutralising antibodies to IFN-a2b were not detected. In two patients 2-5A synthetass in myoloma padents BC Millar and JBG Bell et al 1527 who failed to show induction of the enzyme, there was no way of identifying whether relapse was imminent (Table III , patients 11 and 13). Both of these patients had had HDM with PBSCR.
When enzyme activity was compared in purified T cells and MNCs from three patients who were receiving IFN-a2b there was substantially more enzyme activity in the T-cell fraction (Table IV) . However, both B cells and T cells produced substantial amounts of 2,5-A synthetase following overnight exposure to recombinant IFN-a2b in vitro (Table  V) .
Discussion
At the Royal Marsden Hospital the majority of newly diagnosed patients with multiple myeloma will receive maintenance therapy with IFN-a2b after intensive therapy with HDM/PBSCR. This is based on the encouraging results from an ongoing study in which more than 50% of patients who entered CR after HDM/ABMR followed by maintenance therapy with the cytokine remained in remission for more than 4 years and have had a significant survival advantage (Cunningham et al., 1993) . The mechanism(s) which is involved in mediating these effects are unclear.
In (Griffiths and Cawley, 1988 ) is involved in the anti-tumour response in haematological malignancies.
In an interleukin 6 (IL-6) dependent myeloma cell line IFN-o inhibits proliferation in vitro by depriving cells of , 1994) . Other workers have suggested that a similar mechanism may be involved in the anti-proliferative effect of IFN-x in patients with hairy cell leukaemia and B-cell leukaemia and that it may be mediated by 2,5-A synthetase (Heslop et al., 1991) . In this study, there was no correlation between disease status after intensive therapy for multiple myeloma and our ability to measure 2,5-A synthetase. The finding that the enzyme was not measurable in a significant number of patients suggests that resistance to induction of this protein by can develop early during treatment. In CML, resistance to IFN-x has been ascribed to post-translational modification of the enzyme since there was no consistent defect in the expression of mRNA transcripts for 2,5-A synthetase in patients who were resistant or sensitive to the cytokine (Talpaz et al., 1992) .
Among patients who had measurable levels of 2,5-A synthetase there was considerable inter-patient variation, in agreement with earlier studies (Merritt et al., 1985) but there was no correlation between the magnitude of the enzyme activity and response to intensive therapy. Some of this variability is likely to be due to the distribution of cell types within individual samples and the contribution that each cell type makes to the total enzyme activity in the MNC fraction. In our patients, T lymphocytes were a major source of the enzyme, however it is likely that both B and T cells contribute to enzyme activity in vivo since both cell types showed enzyme induction after exposure in vitro to .
The loss of enzyme activity at progressive disease in three patients suggests that the mechanism(s) which maintains multiple myeloma in a non-proliferative state can be evaded in the absence of 2,5-A synthetase. However, it is not proof that 2,5-A synthetase is a prerequisite for maintaining tumour homeostasis. Once tumour cell proliferation had been initiated in vivo, subsequent recovery of the enzyme as in the patient who continued to receive IFN-m2b during relapse, was not accompanied by inhibition of tumour cell proliferation. Furthermore, 2,5-A synthetase was not detected in three patients who remain in long-term remission but was found in nine patients at presentation. In a study of seven patients receiving IFN-x for hairy cell leukaemia, one of two nonresponders had similar levels of 2,5-A synthetase to those found in patients who responded to the cytokine (Billard et al., 1988) . Collectively this report and our data suggest that other mechanisms which do not involve 2,5-A synthetase may be involved in the anti-tumour effect of In the study of IFN-x as maintenance therapy for multiple myeloma by the South West Oncology Group, although IFN-m2b alone was ineffective, addition of glucocorticoids improved the clinical outcome (Salmon et al., 1994) . The authors proposed that long-term glucocorticoid administration in multiple myeloma during both remission induction and maintenance may result in the best survival overall. At the Royal Marsden Hospital all patients who have had HDM/ABMR received methylprednisolone 1 g m2 for 5 days immediately after HDM and before the start of maintenance therapy (Cunningham et al., 1993) . Whether the continued CR of three out of eight of these patients, despite the absence of 2,5-A synthetase, was determined by the glucocorticoid treatment per se or augmented an antiproliferative effect which was independent of the enzyme cannot be resolved. In the current treatment protocol patients who have had HDM/PBSCR have not had methylprednisolone after HDM. The finding that two patients who have relapsed from CR after HDM/PBSCR at 20 months (patient 9) and 10 months (patient 14) following a decline in 2,5-A synthetase while receiving IFN-a2b may be relevant to this proposition. Whether administration of methylprednisolone after HDM/ABMR has been a determining factor in the prolongation of remission and/or survival benefit in patients who achieved CR and were given IFN-o2b subsequently may become apparent as patients are followed who have PBSCR.
In conclusion, the findings that some patients did not produce 2,5-A synthetase while receiving the cytokine suggests either that IFN--2b was inactive in these patients or that induction of this enzyme is irrelevant to the suppression of the malignant clone by IFN-x2b. In other haematological malignancies the correlation between 2,5-A synthetase levels and clinical response occurs in patients who receive IFN-a2b as sole treatment (de Mel et al., 1990; Ho et al., 1992) suggesting that enzyme levels reflect an antiproliferative effect. However, this may not be analogous to the conditions in our patients who have had intensive therapy before receiving the cytokine and in whom IFN-a2b is given to prolong the response to HDM rather than illicit tumour cell kill. Although the mechanism(s) involved in tumour growth inhibition remains elusive the data suggest that there is a critical balance between the tumour mass and its proliferative state which must be achieved to enable IFN-a2b to maintain homeostasis. Further studies may determine whether restoration of normal haemopoiesis, which may effect tumour homeostasis, occurs independently of the induction of 2,5-A synthetase in multiple myeloma patients receiving IFN-a2b as maintenance therapy. Such studies may result in a more effective and economical use of an expensive resource.
